ConductScience.org, home

Paper42979366PubMed

Biomimetic tumor microenvironment-responsive prodrug amplifies photoimmunotherapy via TLR2 agonist.

Zhi S and 5 others. Acta Pharm Sin B, 2026.

Cite this record

ConductScience Library. Biomimetic tumor microenvironment-responsive prodrug amplifies photoimmunotherapy via TLR2 agonist. Papers, record 42979366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42979366

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Biomimetic tumor microenvironment-responsive prodrug amplifies photoimmunotherapy via TLR2 agonist.
Journal
Acta Pharm Sin B
Year
2026
Publication types
Journal Article
Revised in PubMed
2026-11-05

Source PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhi SSiying
2Huang MMeixin
3Liang EEn
4Xu LLeisheng
5Huang LLan
6Cheng KKui

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References48

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
140123475Near-Infrared Light-Responsive Immunomodulator Prodrugs Rejuvenating Immune Microenvironment for "Cold" Tumor Photoimmunotherapy.Angew Chem Int Ed Engl2025https://conductscience.org/library/papers/40123475PubMed
235879449The complex role of tumor-infiltrating macrophages.Nat Immunol2022https://conductscience.org/library/papers/35879449PubMed
335652198Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency.Adv Sci (Weinh)2022https://conductscience.org/library/papers/35652198PubMed
439173439Cellular and molecular mechanisms of gastrointestinal cancer liver metastases and drug resistance.Drug Resist Updat2024https://conductscience.org/library/papers/39173439PubMed
538326563Dendritic cells as orchestrators of anticancer immunity and immunotherapy.Nat Rev Clin Oncol2024https://conductscience.org/library/papers/38326563PubMed
638551889Immunologic tumor microenvironment modulators for turning cold tumors hot.Cancer Commun (Lond)2024https://conductscience.org/library/papers/38551889PubMed
737328642Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy.Nat Rev Clin Oncol2023https://conductscience.org/library/papers/37328642PubMed
837719381Discovery of novel aporphine alkaloid derivative as potent TLR2 antagonist reversing macrophage polarization and neutrophil infiltration against acute inflammation.Acta Pharm Sin B2023https://conductscience.org/library/papers/37719381PubMed
935217344Engineered nanomaterials for synergistic photo-immunotherapy.Biomaterials2022https://conductscience.org/library/papers/35217344PubMed
1037776767Nanoscale coordination polymer synergizes photodynamic therapy and toll-like receptor activation for enhanced antigen presentation and antitumor immunity.Biomaterials2023https://conductscience.org/library/papers/37776767PubMed
1133431631Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future.J Immunother Cancer2021https://conductscience.org/library/papers/33431631PubMed
1236176917Small molecule SMU-CX24 targeting toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy.Acta Pharm Sin B2022https://conductscience.org/library/papers/36176917PubMed
1331406668Imaging Dynamic Peroxynitrite Fluxes in Epileptic Brains with a Near-Infrared Fluorescent Probe.Adv Sci (Weinh)2019https://conductscience.org/library/papers/31406668PubMed
1428288893Redox-responsive theranostic nanoplatforms based on inorganic nanomaterials.J Control Release2017https://conductscience.org/library/papers/28288893PubMed
1532391629Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors.EMBO Mol Med2020https://conductscience.org/library/papers/32391629PubMed
1630243297Advances in redox-responsive drug delivery systems of tumor microenvironment.J Nanobiotechnology2018https://conductscience.org/library/papers/30243297PubMed
1736307534Targeting drugs to tumours using cell membrane-coated nanoparticles.Nat Rev Clin Oncol2023https://conductscience.org/library/papers/36307534PubMed
1833426371The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.Bioact Mater2021https://conductscience.org/library/papers/33426371PubMed
1939633050Evolution of myeloid-mediated immunotherapy resistance in prostate cancer.Nature2025https://conductscience.org/library/papers/39633050PubMed
2029582476Cell Membrane Coating Nanotechnology.Adv Mater2018https://conductscience.org/library/papers/29582476PubMed

See all 48 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42979366

GET https://conductscience.org/api/papers/v1/42979366/references?page=2